CELC vs INDV: Which Stock Is the Better Buy?
Celcuity Inc. and Indivior Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CELC vs INDV, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Celcuity Inc. (CELC) | Indivior Pharmaceuticals, Inc. (INDV) | |
|---|---|---|
| Market cap | $4.4B | $4.5B |
| Revenue (latest FY) | $0 | $1.24B |
| Net income (latest FY) | $-177.04M | $210.00M |
| Revenue growth (5y CAGR) | — | 11.2% |
| Net margin | — | 16.9% |
| Return on equity | -176.1% | -214.3% |
| P/E ratio | — | 19.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full CELC vs INDV breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CELC's full financials → Open INDV's full financials →More comparisons
Frequently asked questions
Which is bigger, CELC or INDV?
Indivior Pharmaceuticals, Inc. is larger by market capitalization — $4.5B versus $4.4B.
Which grows faster, CELC or INDV?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.